Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer

BACKGROUND: The use of a novel strategy known as adaptive abiraterone therapy based on mathematical modeling of evolutionary dynamics of tumor subpopulations was shown in a clinical trial to extend the time to disease progression in patients with metastatic castration-resistant prostate cancer (CRPC...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am Health Drug Benefits
Hlavní autoři: Mason, Neil T., Burkett, Jason M., Nelson, Ryan S., Pow-Sang, Julio M., Gatenby, Robert A., Kubal, Timothy, Peabody, John W., Letson, G. Douglas, McLeod, Howard L., Zhang, Jingsong
Médium: Artigo
Jazyk:Inglês
Vydáno: Engage Healthcare Communications, LLC 2021
Témata:
Business
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8025923/
https://ncbi.nlm.nih.gov/pubmed/33841621
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky